Ep143: Zach Weinberg and Alexis Borisy on Freeing the Biotech Founders

Episode Summary

Executive Summary: The episode profiles Curie Bio, a $520M biotech venture firm founded by Zach Weinberg and Alexis Borisi to back early-stage therapeutics with both capital and hands-on R&D support. Their thesis: biotech founders are overburdened early, so Curie aims to lower failure risk, preserve founder ownership/control, and make biotech entrepreneurship more like lean tech startups—without losing scientific rigor.

Main Topics: Curie Bio’s founder-friendly venture model (Priority: 5/5): Curie combines seed/Series A financing with embedded scientific and operational support, positioning itself as a co-pilot rather than a conventional VC or incubator. Zach Weinberg’s path from tech to biotech (Priority: 4/5): Weinberg traces his journey from software entrepreneur (Invite Media, Google) to healthcare entrepreneur (Flatiron Health), where he learned the limits of late-stage optimization. Alexis Borisi’s biotech-building background (Priority: 4/5): Borisi describes his route through academia, consulting, founding multiple biotech companies, and later venture investing at Third Rock, giving him a broad view of biotech company formation. Why biotech needs a different startup model (Priority: 5/5): The speakers argue that early therapeutic development is more complex and high-stakes than software, making mistakes costlier and access to elite expertise harder for founders. Founder ownership, control, and dilution (Priority: 5/5): Curie’s “free the founders” philosophy argues biotech entrepreneurs should retain more equity and decision-making authority than is typical in the sector. Net-new entrepreneurship and talent access (Priority: 4/5): Curie wants to widen who can start biotech companies, including postdocs, industry veterans, retired executives, and first-time founders with strong ideas but limited networks. Measuring success through efficient shots on goal (Priority: 4/5): Success is framed as enabling more startups to reach meaningful data, progress to A/B/C rounds, and ultimately produce new therapies and more founders.

Key Arguments: Biotech founders face higher consequence of error than software founders; early mistakes in target selection, experiment design, or vendor choice can waste months and millions. Providing capital alone is insufficient in therapeutics; early companies also need embedded scientific, operational, and strategic expertise. Founder ownership and control should be preserved because it improves agency, commitment, and long-term company-building outcomes. A leaner, more externalized model can convert fixed startup costs into variable costs, making early biotech experimentation faster and cheaper. The industry is seeing technology-driven efficiency gains similar to software’s cloud revolution, but biology still requires human expertise to use those tools well. Curie intentionally focuses on the seed stage to maximize the quality of the data that will attract larger A-round financing later. Biotech entrepreneurship is not saturated; there remains a large pool of underused ideas and potential founders across age and experience levels.

Data Points: Curie Bio fund size: $520 million - Capital raised for early-stage biotech investing, mainly seed and Series A. Typical Curie check size: $5 million to $10 million - Early-stage investments in therapeutics companies. Curie seed fund ownership: ~33% to 40% - Approximate equity stake Curie takes in seed financings. Sweat equity taken by Curie: 7.5% - Equity received for services/support provided to portfolio companies. Current team size: ~38 employees - Full-time Curie staff at the time of the conversation. Planned team size: ~70 employees within 12 months - Expected growth of Curie’s in-house support organization. Curie investments so far: 7 investments - Number of portfolio companies mentioned during the interview. Near-term additional investments: 2 more planned - Expected to bring the portfolio to roughly a dozen companies soon. Expected failure rate: At least 50% - Internal expectation for seed-stage portfolio attrition. Invite Media sale: Sold to Google in 2010 - Weinberg’s first company and entry point into tech entrepreneurship. Flatiron Health sale: Sold to Roche/Genentech in 2018 for about $2 billion - Weinberg’s healthcare company exit. Foundation Medicine transaction: 2015 controlling interest; 2018 remainder acquired - Borisi’s company was acquired in two stages by Roche. One cited early biotech Series A size: $15 million - Borisi compares early 2000s biotech financing to later much larger rounds. Later biotech Series A size: $100 million+ - Illustrates how biotech round sizes grew over time. Example company progress: Single-digit millions of dollars - Forward Therapeutics advanced multiple programs efficiently on a small seed budget.

Pivotal Quotes: "“free the founders”" — Zach Weinberg / Curie Bio: The firm’s central battle cry about preserving founder ownership and control. "“It’s their company. The founders, they still control the company.”" — Alexis Borisi: Clarifies that Curie is a co-pilot, not a controlling venture creator. "“We are really focused on helping the founders that have a really compelling creative idea that can make a difference for patients to as efficiently and as effectively as possible show whether their idea really has merit.”" — Zach Weinberg: Defines Curie’s seed-stage mission and emphasis on rapid validation.

Implications: Curie Bio signals a shift toward leaner, founder-friendly biotech creation: smaller rounds, more embedded expertise, less dilution, and broader access for nontraditional entrepreneurs. If it works, biotech startup formation could become faster, cheaper, and more inclusive.